Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
EKSO BIONICS HOLDINGS, INC. issued 5,852 shares of the Company's newly designated Series B Convertible Preferred Stock of preferred stock to certain institutional and accredited investors for stated value of $1,000 per share.
- Security
- preferred stock
- Shares
- 5,852 shares of the Company's newly designated Series B Convertible Preferred Stock
- Purchaser
- certain institutional and accredited investors
- Consideration
- stated value of $1,000 per share
Exact text from the filing
On January 20, 2026, Ekso Bionics Holdings, Inc. (the “Company”) entered into securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) an aggregate of 5,852 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0.001 per share and stated value (the “Stated Value”) of $1,000 per share (the “Series B Preferred Stock”)
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
EKSO BIONICS HOLDINGS, INC. issued up to an aggregate of 355,960 shares of Common Stock of warrant to certain institutional and accredited investors for exercise price of $8.22 per share.
- Security
- warrant
- Shares
- up to an aggregate of 355,960 shares of Common Stock
- Purchaser
- certain institutional and accredited investors
- Consideration
- exercise price of $8.22 per share
Exact text from the filing
warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of Common Stock at an exercise price of $8.22 per share of Common Stock
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
EKSO BIONICS HOLDINGS, INC.: Filed a Certificate of Designation for Series B Convertible Preferred Stock to the Restated Articles of Incorporation (effective 2026-01-22).
- Change
- charter amendment
- Effective
- 2026-01-22
Exact text from the filing
In connection with the Private Placement, on January 22, 2026, the Company filed a Certificate of Designation of the Powers, Preferences and Relative, Participating, Option and Other Restrictions of the Series B Preferred Stock (the “Certificate of Designation”) to the Company’s Restated Articles of Incorporation with the Secretary of State of the State of Nevada.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
EKSO BIONICS HOLDINGS, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at approximately $5.3 million (effective 2026-01-20).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional and accredited investors
- Value
- approximately $5.3 million
- Effective
- 2026-01-20
Exact text from the filing
On January 20, 2026, Ekso Bionics Holdings, Inc. (the “Company”) entered into securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) an aggregate of 5,852 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0.001 per share and stated value (the “Stated Value”) of $1,000 per share (the “Series B Preferred Stock”) convertible into an aggregate of 711,922 shares (the “Conversion Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) at a conversion price of $8.22 per share, subject to certain customary adjustments, and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of Common Stock at an exercise price of $8.22 per share of Common Stock.
View on SEC.gov